CG ONCOLOGY
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. CG Oncology acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.
CG ONCOLOGY
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2010-01-01
Address:
Irvine, California, United States
Country:
United States
Website Url:
http://www.cgoncology.com
Total Employee:
11+
Status:
Active
Contact:
949-200-7680
Total Funding:
92.57 M USD
Technology used in webpage:
Google Apps For Business Google Maps Google Maps API Namecheap DNS
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Audeo Oncology Inc
Audeo Oncology is a biopharmaceutical company utilizing hyaluronic acid chemotransport technology.
Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer.
Cellular Biomedicine Group
CBMG is a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Prothena
Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies.
Current Employees Featured
Amy Steele Vice President, Controller @ CG Oncology
Vice President, Controller
2016-01-01
Alex Yeung CEO @ CG Oncology
CEO
Bing Kung Vice President of Business Development @ CG Oncology
Vice President of Business Development
Arthur Kuan Chief Executive Officer @ CG Oncology
Chief Executive Officer
2014-01-01
Paola Grandi Chief Scientific Officer @ CG Oncology
Chief Scientific Officer
2018-01-01
Founder
Investors List
ORI Capital
ORI Capital investment in Series D - CG Oncology
Camford Capital
Camford Capital investment in Series D - CG Oncology
Kissei Pharmaceutical
Kissei Pharmaceutical investment in Series D - CG Oncology
Perseverance Capital Management
Perseverance Capital Management investment in Series D - CG Oncology
ORI Capital
ORI Capital investment in Series C - CG Oncology
Perseverance Capital Management
Perseverance Capital Management investment in Series C - CG Oncology
Whitesun Healthcare Ventures
Whitesun Healthcare Ventures investment in Series B - CG Oncology
Ally Bridge Group
Ally Bridge Group investment in Series B - CG Oncology
Song Hong Fang
Song Hong Fang investment in Series B - CG Oncology
WI Harper Group
WI Harper Group investment in Series B - CG Oncology
Official Site Inspections
http://www.cgoncology.com
- Host name: 69.19.212.35.bc.googleusercontent.com
- IP address: 35.212.19.69
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "CG Oncology"
CG Oncology | - Bladder cancer | Oncolytic immunotherapy
Dec 11, 2024 CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients …See details»
Documents & Charters - CG Oncology
CG ONCOLOGY, INC. 400 Spectrum Center Drive Suite 2040 Irvine, CA 92618See details»
CG Oncology, Inc. (CGON) Company Profile & Facts
See the company profile for CG Oncology, Inc. (CGON) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...See details»
CG Oncology - Crunchbase Company Profile & Funding
CG Oncology formerly known as Cold Genesys is a privately held, clinical-stage biopharmaceutical company that focuses on the research, acquisition, and …See details»
Committee Composition - CG Oncology
CG ONCOLOGY, INC. 400 Spectrum Center Drive Suite 2040 Irvine, CA 92618See details»
Investor FAQs | CG Oncology
Find answers to common investor questions about CG Oncology. Please contact our transfer agent, Broadridge Corporate Issuer Solutions, by telephone at (844) 998-0339.See details»
CG Oncology - LinkedIn
CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for …See details»
News | Upcoming Conferences | Media Contact | CG Oncology
Dec 5, 2023 bd@cgoncology.com. Kimberly Ha KKH Advisors (917) 291-5744 kimberly.ha@kkhadvisors.com. Upcoming Conferences Form. I would like to meet with CG …See details»
CG Oncology Announces Closing of Public Offering and Full …
IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a …See details»
CG Oncology to Present at the TD Cowen 45th Annual Health Care ...
Feb 26, 2025 sarah.connors@cgoncology.com. Investor Relations Chau Cheng VP, Investor Relations (949) 342-8939 chau.cheng@cgoncology.com.See details»
CG Oncology - Overview, News & Similar companies - ZoomInfo
Jul 24, 2024 CG Oncology contact info: Phone number: (949) 409-3700 Website: www.cgoncology.com What does CG Oncology do? CG Oncology is a late-stage clinical …See details»
CG Oncology to Participate in the 120th American Urological
1 day ago To learn more, please visit: www.cgoncology.com. Contacts: Media Sarah Connors Vice President, Communications and Patient Advocacy, CG Oncology (508) 654 …See details»
CG Oncology Announces Closing of Public Offering and Full …
IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a …See details»
CG Oncology Announces Pricing of Public Offering
IRVINE, Calif. (BUSINESSWIRE) – CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone …See details»
CG Oncology (CGON) Stock Price, News & Analysis - MarketBeat
Mar 26, 2025 cgoncology.com. Phone 949-419-6203. Fax N/A. Employees 61. Year Founded N/A. Price Target and Rating. Average Stock Price Target $63.88. High Stock Price Target …See details»
CG Oncology Announces Closing of Public Offering and Full
Dec 16, 2024 sarah.connors@cgoncology.com. Investor Relations Chau Cheng VP, Investor Relations (949) 342-8939 chau.cheng@cgoncology.com. TagsSee details»
CG Oncology to Participate in the 120th American Urological …
2 days ago Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials in Urology Additional updates from …See details»
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy …
Dec 5, 2024 sarah.connors@cgoncology.com. Investor Relations Chau Cheng Vice President, Investor Relations, CG Oncology (949) 342-8939 chau.cheng@cgoncology.com. CG …See details»
Abstracts and Presentations - CG Oncology
Browse CG Oncology's latest abstracts and presentations on cancer research, immunotherapy, and clinical trials.See details»
News Articles about CG Oncology
Jan 3, 2024 UROTODAY. December 4, 2023 Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk …See details»